Get the Stockscreener App
0.83
12.22%
-0.1155
Avenue Therapeutics Inc stock is traded at $0.83, with a volume of 111.76K.
It is down -12.22% in the last 24 hours and down -38.97% over the past month.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
See More
Previous Close:
$0.9455
Open:
$0.93745
24h Volume:
111.76K
Relative Volume:
0.30
Market Cap:
$1.95M
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.2178
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
-17.00%
1M Performance:
-38.97%
6M Performance:
-70.46%
1Y Performance:
-93.45%
1-Day Range:
$0.79
$0.973
1-Week Range:
$0.79
$1.0697
52-Week Range:
$0.79
$13.12
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.83 | 1.95M | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.00 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.82 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.73 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
239.23 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.65 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Avenue Therapeutics stock hits 52-week low at $0.9 amid downturn - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com
Avenue Therapeutics Annji Intends To Terminate License Agreement With Co -March 07, 2025 at 04:36 pm EST - Marketscreener.com
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - Nasdaq
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February - Defense World
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World
KESTRA MEDICAL TECHNOLOGIES, LTD. Prices IPO at $14.00-$16.00 Per Share (KMTS) - Defense World
Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World
American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World
Arbe Robotics Ltd. (NASDAQ:ARBE) Short Interest Up 56.5% in February - Defense World
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade - Defense World
Avenue Therapeutics stock hits 52-week low at $1.22 - Investing.com
Avenue Therapeutics stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Avenue Therapeutics (NASDAQ:ATXI) vs. Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World
Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World
The Surprise Surge: How Travere Therapeutics Defied Wall Street Trends - Jomfruland.net
Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN
ATXIAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - br.ADVFN.com
Sionna Therapeutics Prices Upsized Initial Public Offering - GlobeNewswire
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance
Here’s Why Third Avenue Small-Cap Value Fund Re-established a Position in Five Point Holdings (FPH) - Yahoo Finance
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - ACCESS Newswire
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Trajan Group Director Increases Stake Through Options - MSN
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register
Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - ACCESS Newswire
Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Wall Street-Heavily Traded - WDRB
PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World
Fortune Brands plans Deerfield headquarters expansion, hundreds of new jobs; ‘A great endorsement of Lake County’ - Chicago Tribune
Healthcare Triangle Faces Potential Delisting, Plans Annual Meeting - MSN
Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Another strong year for K Street heading into Trump 2.0, tax fights - POLITICO
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World
Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avenue Therapeutics Inc Stock (ATXI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KRANZLER JAY D | Director |
Nov 05 '24 |
Sale |
2.24 |
61 |
137 |
559 |
| KRANZLER JAY D | Director |
Sep 30 '24 |
Buy |
2.50 |
497 |
1,242 |
620 |
| KRANZLER JAY D | Director |
Sep 27 '24 |
Buy |
2.40 |
3 |
7 |
123 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):